Monthly Archives: October 2013

Trends Really Matter – Ask Safeway and Aldi

On 11 October Safeway announced it was going to either sell or close its 79 Dominick's brand grocery stores in Chicago.  After 80 years in Chicago, San Francisco based Safeway leadership felt  it was simply time for Dominick's to call it quits. 

The grocery industry is truly global, because everyone eats and almost nobody grows their own food.  It moves like a giant crude oil carrier, much slower than technology, so identifying trends takes more patience than, say, monitoring annual smartphone  cycles.  Yet, there are clearly pronounced trends which make a huge difference in performance. 

Good for those who recognize them.  Bad for those who don't.

Safeway, like a lot of the dominant grocers from the 1970s-1990s, clearly missed the trends. 

Coming out of WWII large grocers replaced independent neighborhood corner grocers by partnering with emerging consumer goods giants (Kraft, P&G, Coke, etc.) to bring customers an enormous range of products very efficiently.  They offered a larger selection at lower prices.  Even though margins were under 10% (think 2% often) volume helped these new grocery chains make good returns on their assets. Dillon's (originally of Hutchinson, Kansas and later purchased by Kroger) became a 1970s textbook, case study model of effective financial management for superior returns by Harvard Business School guru William Fruhan.

But times changed.

Looking at the trend toward low prices, Aldi from Germany came to the U.S. market with a strategy that defines the ultimate in low cost.  Often there is only one brand of any product in the store, and that is likely to be the chain's private label.  And often it is only available in one size.  And customers must be ready to use a quarter to borrow the shopping cart (returned if you replace the cart.) And customers pay for their sacks.  Stores are remarkably small and efficient, frequently with only 2 or 3 employees. And with execution so well done that the Aldi brand became #1 in "simple brands" according to a study by brand consultancy Seigal+Gale.

Of course, we also know that big discount chains like WalMart and Target started cherry picking the traditional grocer's enormous SKU (stock keeping units) list, limiting selection but offering lower prices due to lower cost. 

Looking at  the quality trend, Whole Foods and its brethren demonstrated that people would pay more for better perceived quality.  Even though filling the aisles with organic
products and the ultimate in freshness led to higher prices, and someone nicknaming the chain
"whole paycheck," customers payed up to shop there, leading to superior
returns.

Connected to quality has been the trend, which began 30 years ago, to "artisanal" products.  Shoppers pay more to buy what are considered limited edition products that are perceived as superior due to a range of "artisanal quality" features; from ingredients used to age of product (or "freshness,") location of manufacture ("local,") extent to which it is considered "organic," quantity of added ingredients for preservation or vitamin enhancement ("less is more,") ecological friendliness of packaging and even producer policies regarding corporate social and ecological responsibility. 

But after decades of partnership, traditional grocers today remain dependant on large consumer goods companies to survive.  Large CPGs supply a massive number of SKUs in a limited number of contracts, making life easy for grocery store buyers.  Big CPGs pay grocers for shelf space, coupons to promote customer purchases, rebates, ads in local store circulars, discounts for local market promotions, sales volumes exceeding commitments and even planograms which instruct employees how to place products on shelves — all saving money for the traditional grocer. In some cases payments and rebates equalling more than total grocer profits. 

Additionally, in some cases big CPG firms even deliver their products into the store and stock shelves at no charge to the grocer (called store-door-delivery as a substitute for grocer warehouse and distribution.) And the big CPG firms spend billions of dollars on product advertising to seemingly assure sales for the traditional grocer.

These practices emerged to support the bi-directionally beneficial historically which tied the traditional grocer to the large CPG companies.  For decades they made money for both the CPG suppliers and their distributors.  Customers were happy. 

But the market shifted, and Safeway (including its employees, customers, suppliers and investors) is the loser.

The old retail adage "location, location, location" is no longer enough in grocery.  Traditional grocery stores can be located next to good neighborhoods, and execute that old business model really well, and, unfortunately, not make any money.  New trends gutted the old Safeway/Dominick's business model (and most of the other traditional grocers) even though that model was based on decades of successful history.

The trend to low price for customers with the least funds led them to shop at the new low-price leaders. And companies that followed this trend, like Aldi, WalMart and Target are the winners. 

The trend to higher perceived quality and artisanal products led other customers to retailers offering a different range of products.  In Chicago the winners include fast growing Whole Foods, but additionally the highly successful Marianno's division of Roundy's (out of Milwaukee.)  And even some independents have become astutely profitable competitors.  Such as Joe Caputo & Sons, with only 3 stores in suburban Chicago, which packs its parking lots daily by offering products appealing to these trendy shoppers.

And then there's the Trader Joe's brand. Instead of being all things to all people, Aldi created a new store chain designed to appeal to customers desiring upscale products, and named it Trader Joe's.  It bares scance resemblance to an Aldi store.  Because it is focused on the other trend toward artisinal and quality.  And it too brings in more customers, at higher margin, than Dominick's.

When you miss a trend, it is very, very painful.  Even if your model worked for 75 years, and is tightly linked to other giant corporations, new trends lead to market shifts making your old success formula obsolete. 

Simultaneously, new trends create opportunities.  Even in enormous industries with historically razor-thin margins – or even losses.  Building on trends allows even small start-up companies to compete, and make good profits, in cutthroat industries – like groceries. 

Trends really matter.  Leaders who ignore the trends will have companies that suffer.  Meanwhile, leaders who identify and build on trends become the new winners.

Leave a comment

Filed under Current Affairs, Defend & Extend, Food and Drink, Leadership, Lifecycle

How the Game Changed Against Big Pharma – Creating New Opportunities

In 1985 there was universal agreement that investors should
be heavily in pharmaceuticals. 
Companies like Merck, Eli Lilly, Pfizer, Sanofi, Roche, Glaxo and Abbott
were touted as the surest route to high portfolio returns.

Today, not so much.

Merck, once a leader in antibiotics, is laying off 20% of
its staff
.  Half in R&D; the
lifeblood of future products and profits. 
 Lilly is undertaking
another round of 2013 cost cuts.  Over
the last year about 100,000 jobs have been eliminated in big pharma companies,
which have implemented spin-outs and split-ups as well as RIFs.

What happened? In the old days pharma companies had to demonstrate
their drug worked; called product efficacy.  It did not have to be better than existing drugs.  If the drug worked, without big safety
issues, the company could launch it.

Then the business folks took over with ads, distribution,
salespeople and convention booths, convincing doctors to prescribe and us to
buy.

Big pharma companies grew into large, masterful consumer
products companies. Leadership’s view of the market changed, as it was
perceived safer to invest in Pepsi vs. Coke marketing tactics and sales warfare
to dominate a blockbuster category than product development.  Think of the marketing cost in the
Celebrex vs. Vioxx war.  Or Viagra
vs. Cialis.

But the market shifted when the FDA decided new drugs had to
be not only efficacious, they had to enhance the standard of care.  New drugs actually had to prove better in clinical trials than existing
drugs.  And often safer, too.

Hurrumph. Big pharma’s enormous scale advantages in
marketing and communication weren’t enough to assure new product success.  It actually took new products.  But that meant bigger R&D investments,
perceived as more risky, than the new consumer-oriented pharma companies could
tolerate.  Shortly pipelines
thinned, generics emerged and much lower margins ensued.

In some disease areas, this evolution was disastrous for
patients.  In antibiotics,
development of new drugs had halted. 
Doctors repeatedly prescribed (some say overprescribed) the same antibiotics.  As the bacteria evolved, infections
became more difficult to treat.

With no new antibiotics on the market the risk of death from
bacterial infections grew, leading to a national public health crisis.  According to the Centers for Disease
Control (CDC)
there are over 2 million cases of antibiotic resistant infections
annually.  Today just one type of
resistant “staph infection,” known as MRSA, kills more people in the USA than
HIV/AIDs – killing more people every year than polio did at its peak. The most
difficult to treat pathogens (called ESKAPE) are the cause of 66% of hospital
infections.

And that led to an important market shift – via regulation
(Congress?!?!)

With help from the CDC and NIH, the Infectious Diseases
Society of America
pushed through the GAIN (Generating Antibiotic Incentives
Now) Act (H.R. 2182.)  This gave
creators of new antibiotics the opportunity for new, faster pathways through
clinical trials and review in order to expedite approvals and market launch.

Additionally new product market exclusivity was lengthened an additional 5
years
(beyond the normal 5 years) to enhance investor returns.

Which allowed new game changers like Melinta Therapeutics
into the game.

Melinta (formerly Rib-X) was once considered a “biopharma science
company” with Nobel Prize-winning technology, but little hope of commercial
product launch.  But now the large
unmet need is far clearer, the playing field has few to no large company
competitors, the commercialization process has been shortened and cheapened,
and the opportunity for extended returns is greater!

Venture firm Vatera Healthcare Partners, with a history of investing in game changers (especially transformational technology,) entered the picture as lead investor.  Vatera's founder Michael Jaharis quickly hired Mary Szela, the former head of U.S.
Pharmaceuticals for Abbott (now Abbvie) as CEO.  Her resume includes leading the growth of Humira, one of
the world’s largest pharma brands with multi-billion dollar annual sales.

Under her guidance Melinta has taken fast action to work
with the FDA on a much quicker clinical trials pathway of under 18 months for
commercializing delafloxacin.  In layman’s
language, early trials of delafloxacin appeared to provide better performance
for a broad spectrum of resistant bacteria in skin infections.  And as a one-dose oral (or IV)
application it could be a simpler, high quality solution for gonorrhea.

Melinta continues adding key management resources as it
seeks “breakthrough product” designation under GAIN from the FDA for its RX-04
product
.  RX-04 is an entirely
different scientific approach to infectious disease control, based on that previously
mentioned proprietary, Nobel-winning ribosome science.   It’s a potential product category
game changer that could open the door for a pipeline of follow-on products.

Melinta is using GAIN to do something big pharma, with its
shrinking R&D and commercial staff, is unable to accomplish. Melinta is helping
redefine the rules for approving antibiotics, in order to push through new,
life-saving products.

The best news is that this game change is great for investors.
 Those companies who understand the
trend (in this case, the urgent need for new antibiotics) and how the market
has shifted (GAIN,) are putting in place teams to leverage newly invented drugs
working with the FDA.  Investment timelines and dollars are looking
far more manageable – and less risky.

Twenty-five years ago pharma looked like a big-company-only
market with little competition and huge returns for a handful of companies.  But things changed.  Now companies (like Melinta) with new
solutions have the opportunity to move much faster to prove efficacy and safety
– and save lives.  They are the
game changers, and the ones more likely to provide not only solutions to the
market but high investor returns.

Leave a comment

Filed under Current Affairs, In the Rapids, Innovation, Lifecycle